Evidence map›Paper›PMID 41743676›Full record

ArticleFrontiers in digital health2026

Monitoring cognition in multiple sclerosis via adaptive smartphone games-first insights from a validation study.

Silvan Pless, Tim Woelfle, Johannes Lorscheider, Andrea Wiencierz, Óscar Reyes, Carlos Luque, Pasquale Calabrese, Cristina Granziera, Ludwig Kappos

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05009160 (DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Validation Study 1), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05009160 active not recruitingnot on this map

DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Validation Study 1

TypeobservationalSponsorResearch Center for Clinical Neuroimmunology and Neuroscience BaselRan2022 to 2027Enrolled300ConditionsMultiple SclerosisArmsdreaMS App R2.1
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Silvan PlessResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Tim WoelfleResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Johannes LorscheiderResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Andrea WiencierzDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Óscar ReyesIndivi AG, Basel, Switzerland.
Carlos LuqueIndivi AG, Basel, Switzerland.
Pasquale CalabreseNeuropsychology and Behavioral Neurology Unit, Department of Psychology and Interdisciplinary Platform Psychiatry and Psychology, Division of Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland.
Cristina GranzieraResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Ludwig KapposResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive impairment in Multiple Sclerosis significantly undermines quality of life and working capacity yet despite its high prevalence (30%-75%) it is often neglected. Gamified and adaptive smartphone tests have great potential to assess cognition reliably and conveniently. To improve monitoring of cognition in people with MS (pwMS) we developed CoGames, a set of 6 adaptive and gamified smartphone tests. Here we present first insights into their reliability, correlations to domain-corresponding reference tests, and adherence. The games were played repeatedly over 6 weeks. We calculated correlation estimates between game-derived measures of the first two runs for the test-retest reliability analysis, correlated (partial Spearman correlation) game measures with the results of established reference tests and assessed adherence as the proportion of played- to scheduled games. We included data collected between March 2022 and October 2023 of the first 100 pwMS, mean age: 46.8 (±12.3), median EDSS: 2.5 (0-7.0), who completed the initial intensive phase of the dreaMS validation study 1 (NCT05009160). Test-retest correlation estimates ranged from r = 0.41 to 0.91. Correlation estimates to reference tests ranged from |ρ| = 0.23 to 0.66. Average adherence was 89.3% (86%-92%). Our results suggest high test-retest reliability of the CoGames and clear correlations with their reference tests. Adherence was higher than for other tests included in the dreaMS app underlining the value of gamification. Albeit these results must be confirmed in a larger population over a longer time, they support the potential of CoGames as a valid, reliable and enjoyable monitoring-tool for cognition in pwMS.

Indexed as

cognitive assessmentcognitive impairmentdigital biomarkersgamificationmonitoring toolmultiple sclerosissmartphone-games

Identifiers

PMID41743676
PMCPMC12930360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.